{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:37:24Z","timestamp":1777415844770,"version":"3.51.4"},"reference-count":13,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Prolymhocytic leukemia (PLL) is a rare subtype of lymphocytic leukemias and its cells are immature lymphocytes. It is divided into 2 subgroups: T-PLL and B-PLL according to the lymphocytic origin of the cells. Discriminating B-PLL from other diseases with clinically-similar features is important because of the different treatment approaches and follow-up programs. Hereby, we report a 80-year-old woman presenting with fatigue, leucocytosis and mild anemia. Her peripheral blood smear evaluation revealed 85% prolymphocytes with moderately condensed nuclear chromatin, prominent nucleoli, and a faintly basophilic cytoplasm. Positron emission tomography-computed tomography showed mediastinal lymph nodes with cervical lymph nodes. There was no pathological FDG involvement in the spleen. Bone marrow aspiration smear exhibit atypical wide lymphocytes with prominent nucleoli and abundant agranular cytoplasm. Flow cytometry analysis revealed positive CD5+, CD19+, CD20+, CD22+, CD11c+, CD25+, CD79a+ and CD79b+. Fluorescence in situ hybridization technique analysis reveals no t(11;14). Bone marrow biopsy revealed interstitially distributed atypical cells with wide nucleus and prominent nucleolus.<\/jats:p>","DOI":"10.4081\/hr.2017.6995","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T11:05:54Z","timestamp":1490180754000},"page":"6995","source":"Crossref","is-referenced-by-count":2,"title":["A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia"],"prefix":"10.3390","volume":"9","author":[{"given":"Alparslan","family":"Merdin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jale","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merih","family":"\u00c7akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmetullah","family":"Batgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Tekgu\u0308ndu\u0308z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aykut","family":"Onursever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","article-title":"Complete response to alemtuzumab in a patient with B prolymphocytic leukaemia","volume":"82","author":"Chaar","year":"2007","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","article-title":"Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia","volume":"96","author":"Bowen","year":"1997","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.1979.tb01159.x","article-title":"Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP","volume":"42","author":"Sibbald","year":"1979","journal-title":"Br J Haematol"},{"key":"ref6","first-page":"Abstract 2499","article-title":"Fludarabine\/cyclophosphamide chemotherapy for B-prolymphocytic leukaemia [abstract]","volume":"102","author":"Herold","year":"2003","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","article-title":"Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"87","author":"Chow","year":"2011","journal-title":"Eur J Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2010.05.003","article-title":"Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment","volume":"37","author":"Robak","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1521-6926(02)00086-5","article-title":"The variant form of hairy-cell leukemia","volume":"16","author":"Matutes","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1309\/8QYTYQ1CLQMHQ9CL","article-title":"Hairy cell leukemia variant: fact or fiction","volume":"123","author":"Cessna","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","article-title":"Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes","volume":"91","author":"Franco","year":"2001","journal-title":"Cancer"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/6995\/6779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/viewFile\/6995\/6830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/9\/1\/6995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:12:02Z","timestamp":1645600322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/9\/1\/6995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2]]}},"alternative-id":["hr.2017.6995"],"URL":"https:\/\/doi.org\/10.4081\/hr.2017.6995","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}